A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
A Multicenter, Post-Market Follow-up Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study
Přehled studie
Postavení
Podmínky
Detailní popis
While studies support the clinical use of ChemoFx® in cancer patients, additional data are needed to further assess the utilization of this product in clinical practice. Such post-market data and information could be employed for product improvement as well as for the development of standards and regulations. This is a multicenter registry study of 3,000 patients with solid tumors. The study is not randomized, nor is it interventional in that the treating physician is free to choose how to employ ChemoFx® results in the clinical management of individual patients. Sites will be selected by Precision's clinical trials team based on past commercial usage of ChemoFx®.
Subjects who may be enrolled in this study are those who have been diagnosed with a solid tumor malignancy and for whom ChemoFx® has been ordered. ChemoFx® is ordered through the normal commercial process and is therefore billed to the patient's medical insurance.
All subjects will be appropriately consented before any study-specific data are collected. A limited dataset of patient demographics, oncology history, and therapeutic intervention will be collected in addition to ChemoFx® assay usage. Subjects will be treated based on the medical judgment of their treating physician(s). Patient survival data will be collected up to five years following the ChemoFx® commercial order. Additional disease progression data may be collected by Precision's CRAs at participating sites.
Optional Cell Research
Informed consent will be obtained to document subject's consent to use excess cells remaining in Precisions' commercial laboratory for additional research. This portion of the study may involve DNA, RNA, and proteomic research. To ensure the anonymity of each subject, any identifiers that would link the sample to the subject will be removed. The samples would then have gene expression profiling and or quantitative protein expression analysis performed. The goal of the research would be to identify a set of informative genes, intermediaries, and proteins and develop predictive algorithm(s) that seek to link the expression level of the gene, gene signature, intermediary, or protein to the clinical outcome of the patient. This portion of the study does not require any additional subject procedures. Neither physicians nor their patients will receive the results of the research performed. Results will not be placed in the subjects health care records and will not affect their medical care.
Typ studie
Zápis (Aktuální)
Kontakty a umístění
Studijní místa
-
-
Alabama
-
Birmingham, Alabama, Spojené státy, 35213
- Cardio-Thoracic Surgeons, P.C.
-
-
California
-
Oakland, California, Spojené státy, 94609
- Hematology Oncology Associates
-
-
Florida
-
Boynton Beach, Florida, Spojené státy, 33435
- Collaborative Research Group
-
Fort Lauderdale, Florida, Spojené státy, 33308
- Broward Oncology Associates, P.A.
-
Hollywood, Florida, Spojené státy, 33021
- The Center For Gynecologic Oncology
-
Miami, Florida, Spojené státy, 33143
- GYN Oncology of Miami
-
Miami, Florida, Spojené státy, 33173
- Miami International Surgical Services
-
Orlando, Florida, Spojené státy, 32804
- Orlando Cardiovascular Institute PA
-
-
Illinois
-
Skokie, Illinois, Spojené státy, 60076
- Edward H. Kaplan, M.D. & Associates
-
-
Iowa
-
Des Moines, Iowa, Spojené státy, 50309
- Iowa Clinic
-
-
Kentucky
-
Lexington, Kentucky, Spojené státy, 40503
- Central Baptist Hospital Clinical Research Center
-
Paducah, Kentucky, Spojené státy, 42003
- Oncology Associates of West Kentucky
-
-
Michigan
-
Grand Blanc, Michigan, Spojené státy, 48439
- Grand Blanc Surgical Specialist
-
-
New York
-
Albany, New York, Spojené státy, 12208
- Albany Thoracic & Esophageal Surgery
-
East Setauket, New York, Spojené státy, 11733
- North Shore Hematology Oncology
-
Flushing, New York, Spojené státy, 11355
- The New York Hospital Medical Center of Queens
-
Mineola, New York, Spojené státy, 11501
- Winthrop University Hospital
-
-
Ohio
-
Cleveland, Ohio, Spojené státy, 44106
- Center for Clinical Research and Technology University Hospitals of Cleveland
-
-
Pennsylvania
-
Erie, Pennsylvania, Spojené státy, 16505
- The Regional Cancer Center
-
-
Texas
-
Houston, Texas, Spojené státy, 77090
- Northwest Cancer Center
-
Houston, Texas, Spojené státy, 77054
- Colorectal Surgical Associates
-
Houston, Texas, Spojené státy, 77024
- Barry S Siller MD
-
San Antonio, Texas, Spojené státy, 78229
- Cancer Care Centers of South Texas
-
-
Washington
-
Spokane, Washington, Spojené státy, 99202
- Cancer Care Northwest
-
-
West Virginia
-
Morgantown, West Virginia, Spojené státy, 26508
- Heiskell, King, Burns & Tallman Surgical Associates, Inc.
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
- Pathologically confirmed diagnosis of solid tumor malignancy;
- Medically indicated to receive chemotherapy;
- Fresh tissue submitted from the solid tumor malignancy for testing with the ChemoFx® assay after August, 2006;
- Final ChemoFx® assay report is available;
- Subject must be at least 18 years of age;
- Subject must sign and date an IRB approved ICF.
Exclusion Criteria:
- Enrolled in PT-103, PT-106, PT-206, PT-301, or PT-304;
- Pregnant or lactating subjects;
- Subjects are not indicated to receive chemotherapy for their disease;
- Subjects with psychiatric or addictive disorders that would preclude obtaining informed consent.
Studijní plán
Jak je studie koncipována?
Detaily designu
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
|---|---|
|
To determine physicians' rate of compliance with ChemoFx assay results in the treatment of subjects with solid tumors.
Časové okno: Analysis of assay-directed compliance will be conducted immediately after information is collected.
|
Analysis of assay-directed compliance will be conducted immediately after information is collected.
|
|
To investigate the association between the results of Precision's ChemoFx assay results and overall survival in subjects with solid tumors.
Časové okno: From date of first dose of on-study chemotherapy to date of death or last known alive.
|
From date of first dose of on-study chemotherapy to date of death or last known alive.
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Karl Williams, M.D., Precision Therapeutics, Inc.
Publikace a užitečné odkazy
Užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- PT-207
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .